Journal article
Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial
Abstract
BACKGROUND: Individuals with frailty are at higher risk of adverse cardiovascular outcomes and bleeding. The objective of this study was to determine whether the effects of 2.5 mg rivaroxaban twice daily in addition to low-dose aspirin are similar among frail compared with nonfrail patients with chronic atherosclerotic vascular disease.
METHODS: In the COMPASS trial (NCT01776424), patients with chronic atherosclerotic vascular disease were …
Authors
Leong DP; Bosch J; Bhatt DL; Avezum A; Yuan F; Yusuf S; Eikelboom JW
Journal
Canadian Journal of Cardiology, Vol. 41, No. 1, pp. 102–111
Publisher
Elsevier
Publication Date
1 2025
DOI
10.1016/j.cjca.2024.06.017
ISSN
0828-282X
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedAged, 80 and overFemaleHumansMaleMiddle AgedAspirinAtherosclerosisCardiovascular DiseasesDrug Therapy, CombinationFactor Xa InhibitorsFrailtyPlatelet Aggregation InhibitorsRivaroxabanSecondary PreventionMulticenter Studies as TopicRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic